Rejection and infection after pediatric cardiac transplantation

Elizabeth A. Braunlin, Charles E. Canter, Maria Teresa Olivari, W. Steves Ring, Thomas L. Spray, R. Morton Bolman

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Cardiac transplantation has only recently become an accepted therapeutic modality for children and adolescents with end-stage cardiomyopathy. Long-term survival, the incidence of rejection, and the incidence of infection are still being defined. From 1985 to 1989, 21 children aged 6 months to 19 years (average age, 11.2 years) underwent cardiac transplantation at our institutions. Eighteen survived the operative period and have been followed for 5 to 49 months (average follow-up, 24 months). All operative survivors have received tripledrug immunosuppression consisting of cyclosporine, azathioprine, and prednisone. During follow-up, 7 patients have been treated on 12 occasions for rejection as documented by endomyocardial biopsy. Eight (67%) of the 12 episodes of rejection occurred in the presence of subtherapeutic cyclosporine levels. Two of the 7 patients treated for rejection have subsequently died of ongoing cardiac rejection and arrhythmia. There have been no perioperative or late deaths from infection. Bacterial sepsis was identified and treated twice during follow-up, viral infections on five occasions, and fungal infection once. Actuarial 1-year survival and 3-year survival of the 18 operative survivors are 94% and 78%, respectively. In the first 7 months after cardiac transplantation, 73% of patients were free from rejection and 83% were free from serious bloodborne infection. We conclude that (1) the incidence of rejection and infection is low with tripledrug immunosuppression; (2) rejection episodes occur must commonly within the first year after cardiac transplantation but can occur late; (3) rejection can often be associated with subtherapeutic cyclosporine levels; (4) major bacterial infection can occur in association with a common disease process but appears to respond to standard antibiotic therapy; and (5) viral infections have been well tolerated by the patients.

Original languageEnglish (US)
Pages (from-to)385-390
Number of pages6
JournalThe Annals of Thoracic Surgery
Volume49
Issue number3
DOIs
StatePublished - 1990

Fingerprint

Heart Transplantation
Pediatrics
Cyclosporine
Virus Diseases
Infection
Immunosuppression
Survival
Survivors
Incidence
Mycoses
Azathioprine
Prednisone
Cardiomyopathies
Bacterial Infections
Cardiac Arrhythmias
Sepsis
Anti-Bacterial Agents
Biopsy
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Braunlin, E. A., Canter, C. E., Olivari, M. T., Ring, W. S., Spray, T. L., & Bolman, R. M. (1990). Rejection and infection after pediatric cardiac transplantation. The Annals of Thoracic Surgery, 49(3), 385-390. https://doi.org/10.1016/0003-4975(90)90241-W

Rejection and infection after pediatric cardiac transplantation. / Braunlin, Elizabeth A.; Canter, Charles E.; Olivari, Maria Teresa; Ring, W. Steves; Spray, Thomas L.; Bolman, R. Morton.

In: The Annals of Thoracic Surgery, Vol. 49, No. 3, 1990, p. 385-390.

Research output: Contribution to journalArticle

Braunlin, EA, Canter, CE, Olivari, MT, Ring, WS, Spray, TL & Bolman, RM 1990, 'Rejection and infection after pediatric cardiac transplantation', The Annals of Thoracic Surgery, vol. 49, no. 3, pp. 385-390. https://doi.org/10.1016/0003-4975(90)90241-W
Braunlin, Elizabeth A. ; Canter, Charles E. ; Olivari, Maria Teresa ; Ring, W. Steves ; Spray, Thomas L. ; Bolman, R. Morton. / Rejection and infection after pediatric cardiac transplantation. In: The Annals of Thoracic Surgery. 1990 ; Vol. 49, No. 3. pp. 385-390.
@article{792ca32ad3a1490984d69836a32125f0,
title = "Rejection and infection after pediatric cardiac transplantation",
abstract = "Cardiac transplantation has only recently become an accepted therapeutic modality for children and adolescents with end-stage cardiomyopathy. Long-term survival, the incidence of rejection, and the incidence of infection are still being defined. From 1985 to 1989, 21 children aged 6 months to 19 years (average age, 11.2 years) underwent cardiac transplantation at our institutions. Eighteen survived the operative period and have been followed for 5 to 49 months (average follow-up, 24 months). All operative survivors have received tripledrug immunosuppression consisting of cyclosporine, azathioprine, and prednisone. During follow-up, 7 patients have been treated on 12 occasions for rejection as documented by endomyocardial biopsy. Eight (67{\%}) of the 12 episodes of rejection occurred in the presence of subtherapeutic cyclosporine levels. Two of the 7 patients treated for rejection have subsequently died of ongoing cardiac rejection and arrhythmia. There have been no perioperative or late deaths from infection. Bacterial sepsis was identified and treated twice during follow-up, viral infections on five occasions, and fungal infection once. Actuarial 1-year survival and 3-year survival of the 18 operative survivors are 94{\%} and 78{\%}, respectively. In the first 7 months after cardiac transplantation, 73{\%} of patients were free from rejection and 83{\%} were free from serious bloodborne infection. We conclude that (1) the incidence of rejection and infection is low with tripledrug immunosuppression; (2) rejection episodes occur must commonly within the first year after cardiac transplantation but can occur late; (3) rejection can often be associated with subtherapeutic cyclosporine levels; (4) major bacterial infection can occur in association with a common disease process but appears to respond to standard antibiotic therapy; and (5) viral infections have been well tolerated by the patients.",
author = "Braunlin, {Elizabeth A.} and Canter, {Charles E.} and Olivari, {Maria Teresa} and Ring, {W. Steves} and Spray, {Thomas L.} and Bolman, {R. Morton}",
year = "1990",
doi = "10.1016/0003-4975(90)90241-W",
language = "English (US)",
volume = "49",
pages = "385--390",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Rejection and infection after pediatric cardiac transplantation

AU - Braunlin, Elizabeth A.

AU - Canter, Charles E.

AU - Olivari, Maria Teresa

AU - Ring, W. Steves

AU - Spray, Thomas L.

AU - Bolman, R. Morton

PY - 1990

Y1 - 1990

N2 - Cardiac transplantation has only recently become an accepted therapeutic modality for children and adolescents with end-stage cardiomyopathy. Long-term survival, the incidence of rejection, and the incidence of infection are still being defined. From 1985 to 1989, 21 children aged 6 months to 19 years (average age, 11.2 years) underwent cardiac transplantation at our institutions. Eighteen survived the operative period and have been followed for 5 to 49 months (average follow-up, 24 months). All operative survivors have received tripledrug immunosuppression consisting of cyclosporine, azathioprine, and prednisone. During follow-up, 7 patients have been treated on 12 occasions for rejection as documented by endomyocardial biopsy. Eight (67%) of the 12 episodes of rejection occurred in the presence of subtherapeutic cyclosporine levels. Two of the 7 patients treated for rejection have subsequently died of ongoing cardiac rejection and arrhythmia. There have been no perioperative or late deaths from infection. Bacterial sepsis was identified and treated twice during follow-up, viral infections on five occasions, and fungal infection once. Actuarial 1-year survival and 3-year survival of the 18 operative survivors are 94% and 78%, respectively. In the first 7 months after cardiac transplantation, 73% of patients were free from rejection and 83% were free from serious bloodborne infection. We conclude that (1) the incidence of rejection and infection is low with tripledrug immunosuppression; (2) rejection episodes occur must commonly within the first year after cardiac transplantation but can occur late; (3) rejection can often be associated with subtherapeutic cyclosporine levels; (4) major bacterial infection can occur in association with a common disease process but appears to respond to standard antibiotic therapy; and (5) viral infections have been well tolerated by the patients.

AB - Cardiac transplantation has only recently become an accepted therapeutic modality for children and adolescents with end-stage cardiomyopathy. Long-term survival, the incidence of rejection, and the incidence of infection are still being defined. From 1985 to 1989, 21 children aged 6 months to 19 years (average age, 11.2 years) underwent cardiac transplantation at our institutions. Eighteen survived the operative period and have been followed for 5 to 49 months (average follow-up, 24 months). All operative survivors have received tripledrug immunosuppression consisting of cyclosporine, azathioprine, and prednisone. During follow-up, 7 patients have been treated on 12 occasions for rejection as documented by endomyocardial biopsy. Eight (67%) of the 12 episodes of rejection occurred in the presence of subtherapeutic cyclosporine levels. Two of the 7 patients treated for rejection have subsequently died of ongoing cardiac rejection and arrhythmia. There have been no perioperative or late deaths from infection. Bacterial sepsis was identified and treated twice during follow-up, viral infections on five occasions, and fungal infection once. Actuarial 1-year survival and 3-year survival of the 18 operative survivors are 94% and 78%, respectively. In the first 7 months after cardiac transplantation, 73% of patients were free from rejection and 83% were free from serious bloodborne infection. We conclude that (1) the incidence of rejection and infection is low with tripledrug immunosuppression; (2) rejection episodes occur must commonly within the first year after cardiac transplantation but can occur late; (3) rejection can often be associated with subtherapeutic cyclosporine levels; (4) major bacterial infection can occur in association with a common disease process but appears to respond to standard antibiotic therapy; and (5) viral infections have been well tolerated by the patients.

UR - http://www.scopus.com/inward/record.url?scp=0025230677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025230677&partnerID=8YFLogxK

U2 - 10.1016/0003-4975(90)90241-W

DO - 10.1016/0003-4975(90)90241-W

M3 - Article

C2 - 2178568

AN - SCOPUS:0025230677

VL - 49

SP - 385

EP - 390

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 3

ER -